Quantum-Si incorporated

Quantum-Si incorporated (QSI) Market Cap

Quantum-Si incorporated has a market capitalization of $210.2M.

Financials based on reported quarter end 2025-12-31

Price: $1.07

0.03 (2.88%)

Market Cap: 210.18M

NASDAQ · time unavailable

CEO: Jeffrey Alan Hawkins

Sector: Healthcare

Industry: Biotechnology

IPO Date: 2020-11-13

Website: https://www.quantum-si.com

Quantum-Si incorporated (QSI) - Company Information

Market Cap: 210.18M · Sector: Healthcare

Quantum-Si incorporated, a life sciences company, develops a single molecule detection platform for sample preparation and sequencing. It offers a proprietary single molecule detection platform for use in semiconductor industry to field proteomics to enable next generation protein sequencing. The company was incorporated in 2013 is based in Guilford, Connecticut.

Analyst Sentiment

72%
Strong Buy

Based on 3 ratings

Analyst 1Y Forecast: $1.50

Average target (based on 2 sources)

Consensus Price Target

Low

$1

Median

$1

High

$1

Average

$1

Downside: -6.5%

Price & Moving Averages

Loading chart...

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 QUANTUM SI INC CLASS A (QSI) — Investment Overview

🧩 Business Model Overview

Quantum Si Inc Class A (QSI) operates in the quantum-technology ecosystem, commercializing advanced quantum-enabled solutions through a mix of research-led engagements and commercialization pathways. The value chain typically spans (i) technology development and intellectual property creation, (ii) integration of quantum-relevant components and software workflows into customer use cases, and (iii) deployment support tied to performance, reliability, and validation requirements.

Customer adoption tends to be project-based initially, followed by longer-term expansion when early deployments validate outcomes. The “how it works” therefore resembles a staged adoption funnel: customers evaluate technical fit, then scale usage if performance targets and operational integration are met. This staged process supports stickiness because switching from one quantum solution architecture to another often requires re-integration of workflows, retraining, and revalidation of system performance.

💰 Revenue Streams & Monetisation Model

QSI’s monetization is commonly characterized by a combination of:

  • Technology and solution sales tied to specific deployments, which may include hardware-linked arrangements and implementation services.
  • Services and support associated with integration, validation, and ongoing optimization—often increasing over time as customers operationalize the technology.
  • Potential recurring elements where customers require continued performance verification, maintenance, or software enablement, though the mix depends on customer-specific deployment models.

Margin drivers are typically influenced by (i) the extent of differentiated technology content, (ii) the degree of repeatable integration components that reduce marginal service effort, and (iii) the balance between project-based labor and standardized productized elements. As customer deployments scale, gross margin can improve if integration and validation become more templated and if supply chain execution is stabilized.

🧠 Competitive Advantages & Market Positioning

The moats for quantum-technology vendors are more often economic switching costs and intangible assets than mature network effects in early commercialization phases.

  • Switching Costs (Hard to replicate): Once a customer invests in system integration, experimental validation, and workflow design around a quantum solution, replacing it generally entails rework across engineering, compliance/testing, and performance benchmarking. That cost structure favors incumbents or proven vendors in subsequent deployment rounds.
  • Intangible Assets (IP and know-how): Quantum-enabled performance depends on specialized IP, system engineering expertise, and operational learning curves. These are difficult to transfer quickly because they embed both patented elements and cumulative practical know-how.
  • Capability-based differentiation: In quantum applications, outcomes hinge on integration quality and system reliability. Competitors can match components, but delivering comparable outcomes within the same operational context is harder, creating a performance-based moat.

Net result: QSI’s competitive position is strongest when customers value validated outcomes and when deployments generate learning that compounds over time—raising the bar for late entrants and reducing the probability of churn once integration is completed.

🚀 Multi-Year Growth Drivers

Growth over a 5–10 year horizon is supported by a set of structural drivers that expand the total addressable market (TAM) even if commercialization proceeds in uneven cycles:

  • Secular enterprise adoption of advanced computation: Increasing experimentation and pilot-to-production transitions in areas where quantum approaches are expected to provide incremental or stepwise advantages.
  • Validation and benchmarking demand: Customers increasingly require proof-of-performance, reliability, and integration capability—supporting a vendor category beyond pure R&D.
  • Platform buildout economics: As vendors standardize components, software layers, and deployment playbooks, the business can scale with less proportional labor intensity.
  • Capital formation and ecosystem development: Growth in supplier networks, research partnerships, and government/industry programs can accelerate commercialization pathways and increase the pipeline of addressable opportunities.

The most durable growth path is the one that converts early deployments into repeatable solutions and long-term customer relationships, thereby shifting revenue quality toward more predictable, supportable demand.

⚠ Risk Factors to Monitor

  • Technological execution risk: Quantum performance is sensitive to system design and integration quality. Any gap between technical roadmaps and realized outcomes can slow customer conversion.
  • Commercialization pacing risk: Customers may extend pilot timelines, shift priorities, or require additional validation steps. This can pressure near-to-intermediate revenue visibility.
  • Capital intensity and funding risk: Continued R&D and scaling can require incremental capital. The business model’s tolerance for dilution or funding constraints should be monitored.
  • Competitive displacement risk: Larger technology firms or specialized competitors may bundle adjacent capabilities. The extent to which QSI maintains differentiation through integration outcomes and IP matters.
  • Regulatory and export-control considerations: Advanced technology markets can be subject to export controls and compliance requirements that affect customer access and geography.

📊 Valuation & Market View

Markets often value quantum and deep-technology companies using blended approaches that reflect:

  • Revenue quality expectations: Investors increasingly focus on whether revenue becomes recurring through support, software enablement, or repeat deployments.
  • Path-to-scale indicators: Operating leverage potential, gross margin trajectory, and evidence that deployments are becoming more repeatable.
  • Intellectual property and technology credibility: Though not captured fully in traditional multiples, credible IP portfolios and technical milestones influence perceived probability-weighted outcomes.

Sector valuation frameworks frequently emphasize forward-looking sales and business-model credibility (sometimes via EV/Revenue or EV/operating metrics) rather than relying exclusively on near-term earnings power. Key valuation drivers typically include execution against productization milestones, customer conversion rates from pilots to scaled deployments, and improvements in unit economics as integration becomes more standardized.

🔍 Investment Takeaway

QSI’s long-term investment case rests on the presence of economic switching costs and intangible assets (IP and integration know-how) in a market where performance validation and system integration are central to adoption. The most investable trajectory is one that converts deployments into repeatable, supportable solutions—raising revenue durability and enabling operating leverage. Risks remain meaningful due to execution and commercialization pacing, but a disciplined assessment of technology credibility, customer conversion, and unit economics can frame a robust multi-year outlook.


⚠ AI-generated — informational only. Validate using filings before investing.

Fundamentals Overview

Loading fundamentals overview...

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"Latest quarter (2025-12-31): Revenue of $451k and net income of -$17.61M (EPS -$0.0842). QoQ, revenue fell from $552k to $451k (-18.3%), while net income improved (loss narrowed) from -$35.70M to -$17.61M (about +50.7% improvement in the income line; i.e., less loss). Over the full 4-quarter span, revenue has been volatile—peaking at $842k (2025-03-31) and trending lower into year-end—while net losses remain consistently large relative to sales (net margin remains deeply negative). Cash flow quality is weak: operating cash flow and free cash flow were negative in every quarter (FCF approximately -$16.3M in the latest quarter), indicating the business is not self-funding operations. Balance sheet resilience appears mixed but reasonably solvent: total equity remains positive and relatively stable (about $220M–$247M across the period), and net debt is negative (net cash position) though it fluctuates. Shareholder returns are currently unfavorable. The stock is down -14.63% over 1Y and -51.16% over 6M, with no evidence of dividend income (dividend yield 0). Total return is therefore primarily negative price performance, with no buyback data provided."

Revenue Growth

Neutral

QoQ revenue declined -18.3% (552k -> 451k). Over the 4-quarter period revenue was volatile (842k peak to 451k latest), with no clear upward trajectory. YoY growth rates were not computable from the provided 2025-only history.

Profitability

Neutral

Net loss persists throughout the period. QoQ loss improved meaningfully (-35.7M -> -17.6M), but profitability remains structurally weak: net income is deeply negative relative to revenue, and margin remains severely negative across quarters.

Cash Flow Quality

Neutral

FCF is negative in all quarters (latest FCF about -$16.3M). Operating cash flow is consistently cash-consuming, implying continued reliance on external funding or balance sheet strength.

Leverage & Balance Sheet

Caution

Equity is positive and broadly stable (roughly $220M–$247M). Net debt is negative (net cash) across quarters, suggesting some resilience, though total assets and leverage fluctuate.

Shareholder Returns

Neutral

Total shareholder return is poor based on available data: price is down -14.63% (1Y) and -51.16% (6M). No dividends are paid and no buybacks were provided.

Analyst Sentiment & Valuation

Neutral

Consensus price target is about $1 versus current price ~$1.05 (slightly below), indicating limited upside per provided target levels. Analyst valuation support appears modest.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Management is positioning 2026 as an explicitly constrained “transition year” to protect Proteus ramp, with very limited new capital sales and revenue driven mainly by consumables. Hard numbers reflect this: guidance of ~ $1.0m revenue, adjusted OpEx of $98m or less, and cash usage of $93m or less, supported by $215.8m liquidity at year-end. The near-term story is not about demand confirmation—Q&A confirms there are no secured Proteus orders/LOIs yet; the $425,000 Proteus list price is being released mainly to enable customer grant/tender capital planning. On the risk side, management repeatedly ties 2025 capital headwinds to NIH funding uncertainty/indirect rates and broader tariff-related uncertainty, and the quarter’s gross margin was pressured by mix and inventory adjustments. Analysts pressed for specifics (consumables utilization, preorder visibility, customer adoption curve), and management gave only qualitative launch-curve expectations and emphasized preparations (grant cycles, partner meeting).

AI IconGrowth Catalysts

  • Installed-base consumables utilization: company expects a >25% increase in number of consumable kits run by customers in 2026
  • Proteus prelaunch momentum from early customer/channel partner engagement, including expanded access to new KOL labs
  • Scientific pipeline expansion: 3 new manuscripts/releases/preprints already in first 2 months of 2026 (from 5 submitted during 2025)
  • Proteus performance improvements over Platinum Pro across key performance metrics (as shown at Oct 2025 I&A Day)

Business Development

  • Instrument acquisition option program (launched Q2 2025): secured 17 new customers across academic labs, pharma, and biotech since launch
  • Potential partnerships being evaluated for enrichment technologies (very low abundance/high-value biomarker analysis) and AI tools for deeper insights from protein sequencing data

AI IconFinancial Highlights

  • Q4 2025 revenue: $451k; gross profit $122k; gross margin 27% (mix impact: higher consumables vs hardware + certain inventory adjustments)
  • FY 2025 revenue: $2.4m; gross profit $1.2m; gross margin 47%
  • Q4 2025 GAAP total operating expenses: $21.2m vs $31.3m prior-year quarter; adjusted OpEx: $18.3m vs $26.7m prior-year quarter
  • FY 2025 GAAP OpEx: $117.3m vs $110.2m; adjusted OpEx: $86.3m vs $99m (cost discipline + targeted R&D for Proteus)
  • Non-recurring FY 2025 GAAP charges: ~$18.7m related to net termination payment + asset write-off (leased facility, New Haven, CT) + litigation settlements/preliminary settlements
  • Dividend/interest income: $2.2m in Q4; $9.7m for FY 2025 (down YoY due to lower interest rates/invested balances)
  • 2026 guidance: revenue ~ $1.0m; adjusted OpEx $98m or less; total cash usage $93m or less
  • Adjusted OpEx guidance is more cash-oriented: adjusted figures exclude stock-based compensation

AI IconCapital Funding

  • Cash position at Dec 31, 2025: $215.8m in cash, cash equivalents, and marketable securities
  • Cash runway guidance: positioned to support operations into Q2 2028 (based on FY-end liquidity and 2026 cash usage guidance of <=$93m)

AI IconStrategy & Ops

  • 2026 characterized as a transition year: revenue primarily driven by consumable utilization from installed base + some new placements; very modest new capital sales
  • Proteus launch timing: targeted for end of 2026
  • Platinum Pro upgrade pass to be embedded in units (near-term revenue impact + customer delayed purchases as they prepare for Proteus)
  • List price pull-forward for Proteus: management moved announcement of list price from Q2 2026 to March 2026 call date
  • Proteus list price announced: $425,000
  • No Proteus secured orders/LOIs disclosed; $425k list price released to support customer grant/tender capital planning

AI IconMarket Outlook

  • Q4 2025 to 2026 transition framing: expecting very limited first-generation Platinum Pro capital purchases due to deliberate market preparation for Proteus
  • 2026 consumables assumption embedded in revenue guide: >25% increase in consumable kits run
  • Proteus prelaunch/transition commercialization expectations (qualitative): existing Platinum/Platinum Pro users transitioning over first 1–2 years of launch; adoption depends on applications available at launch and any transitional financial incentives
  • Channel partner meeting planned (this month per Q&A): intended to assess which partners/markets are best fit for Proteus and how partners will build/install bases

AI IconRisks & Headwinds

  • Capital sales headwinds in 2025: delays in NIH funding, concern around NIH budget and indirect reimbursement rates, and uncertainty around tariffs causing customer capital budgets to be put in limbo
  • Gross margin pressure in Q4 2025 due to revenue mix (higher consumables share vs hardware) and certain inventory adjustments
  • Proteus focus in 2026 expected to impact top-line results due to trade-offs prioritizing platform adoption over near-term instrument revenue
  • No evidence of secured Proteus orders disclosed as of call date (list price released but orders not secured/communicated)
  • A key nuance affecting near-term capital revenue recognition: some customers may request credits for a future Proteus purchase when buying Platinum Pro, which can alter/defers recognized revenue in the short term

Sentiment: CAUTIOUS

Note: This summary was synthesized by AI from the QSI Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
📁

SEC Filings (QSI)

© 2026 Stock Market Info — Quantum-Si incorporated (QSI) Financial Profile